 | |
| Clinical data | |
|---|---|
| Other names | γ-Hydroxyvaleric acid GVB |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.033.516 |
| Chemical and physical data | |
| Formula | C5H10O3 |
| Molar mass | 118.132 g·mol−1 |
γ-Hydroxyvaleric acid (GHV), also known as 4-methyl-GHB, is a designer drug related to γ-hydroxybutyric acid (GHB). It is sometimes seen on the grey market as a legal alternative to GHB, but with lower potency and higher toxicity,[2] properties which have tended to limit its recreational use.[3]
γ-Valerolactone (GVL) acts as a prodrug to GHV, analogously to how γ-butyrolactone (GBL) is a prodrug to GHB.[4]
See also[edit]
References[edit]
- ^ "GHB and Analogues: Fast Facts". National Drug Intelligence Center. January 1, 2006. Archived from the original on July 26, 2023. Retrieved July 5, 2023.
{{cite web}}: CS1 maint: bot: original URL status unknown (link) - ^ Carter LP, Chen W, Wu H, Mehta AK, Hernandez RJ, Ticku MK, et al. (April 2005). "Comparison of the behavioral effects of gamma-hydroxybutyric acid (GHB) and its 4-methyl-substituted analog, gamma-hydroxyvaleric acid (GHV)". Drug and Alcohol Dependence. 78 (1): 91–99. doi:10.1016/j.drugalcdep.2004.10.002. PMID 15769562.
- ^ Smith F (31 December 2004). Handbook of Forensic Drug Analysis. Academic Press. pp. 462–. ISBN 978-0-08-047289-8.
- ^ Andresen-Streichert H, Jungen H, Gehl A, Müller A, Iwersen-Bergmann S (May 2013). "Uptake of gamma-valerolactone--detection of gamma-hydroxyvaleric acid in human urine samples". Journal of Analytical Toxicology. 37 (4): 250–254. doi:10.1093/jat/bkt013. PMID 23486087.